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ABSTRACT
Ceramide is a second messenger involved in apoptosis, cell differentiation, and
growth arrest. We hypothesize that in tumor cells, insufficient sphingomyelin (SM)
limits the amount of ceramide which can be generated for the probagation of the
apoptotic signal resulting from treatment with chemotherapy. As a result, we postulated
that exogenous SM will facilitate apoptosis and synergize with chemotherapeutic agents.
The current studies examined the response of the Panel human pancreatic cancer
cell line to gemcitabine, a nucleoside analog, in the presence and absence of sub-toxic
doses of SM. Cytotoxic dose response relationships demonstrated an increased
chemosensitivity to gemcitabine with SM inclusion which was synergistic. Treatment
with gemcitabine and/or SM led to an increased percentage of apoptotic cells with
combination treatment as compared to the single agents. Gemcitabine treatment caused a
decrease in the expression of anti-apoptotic bcl-2 family proteins in Panel cells,
irrespective of the inclusion of SM. However, treatment of Panel cells with a
combination of gemcitabine and exogenous SM resulted in a greater percentage of cells
accumulating in the S phase when compared to single agent treatments. Changes in
morphology and /3-galactosidase activity in cells treated with gemcitabine were consistent
with senescence and gemcitabine-induced senescence was abrogated by concomitant SM
treatment. Moreover, exposure of Panel cells to Cg-ceramide demonstrated ceramide
induces both apoptosis and senescence in a concentration dependent manner with
senescence occurring at lower concentrations and apoptosis at high concentrations.
These findings support our proposed model which suggests a cell’s ability to
progress through the cell cycle, undergo apoptosis, or enter into senescence is associated
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with intracellular ceramide levels. By supporting ceramide generation via exogenous SM
addition, it is possible to increase apoptosis signaling in tumor cells and increase
gemcitabine cytotoxicity. However, failure to generate sufficient signaling ceramide will
redirect cells to senescence.
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LIST OF FIGURES
Figure 1. Sphingolipid metabolism. De novo synthesis of ceramide begins with the
condensation of serine and palmitoyl CoA to yield sphinganine, followed by acylation to
dihydro ceramide and dehydrogenation to ceramide. Ceramide is then the root of all other
sphingo lipids. The addition of glucose or galactose is the next step in the formation of
higher order gangliosides and is the major use of ceramide. The other major use of
ceramide is the production of SM via the transfer of a phosphocholine headgroup from
phosphatidylcholine by SM synthase. SM may be degraded to ceramide by the action of
SMases. Ceramide may be degraded to sphingosine by the action of ceramidase.
Figure 2. Dose dependent response of Panel cells to gemcitabine in the presence of SM.
Panel cells were treated for 4 days with different concentrations of gemcitabine as a
single agent and in combination with 0.2 mg/ml (ICio) SM before assessment of viability
with MTT reagent. Typical results are shown. The IC5o values were determined to be
78.3 ± 13.7 nM for gemcitabine alone and 13.0 ± 3.0 nM for the combined treatment
(P < 0.001). These values represent the mean ± standard error from > 20 independent
experiments.
Figure 3. Exogenous sphingomyelin uptake in Panel over time. Panel cells were treated
with [3H-methyl]choline-SM and solubilized at 0, 24, 48, 72, and 96 hours. The data
were normalized to total protein levels determined from cells treated with non-radio active
SM. The figure is representative of data obtained from > 3 experiments.
Figure 4. Flow cytometric analysis of Panel cells after gemcitabine ± SM treatment.
Panel cells were treated with 100 nM gemcitabine in the presence or absence of
0.2 mg/ml SM for 4 days. Apoptotic cells were detected by Annexin V-FITC and
propidium iodide staining. (A) Cells in the lower left quadrant are viable, in the upper
and lower right quadrants are apoptotic, and the left and right upper quadrants are dead.
(B) Values correspond with the percentage of healthy (viable, non-apoptotic), apoptotic,
and dead cells in the above experiment. The figure is representative of data obtained
from separate experiments with similar results.
Figure 5. Aggregated data for apoptotic Panel cells. Panel cells were treated with
100 nM gemcitabine in the presence or absence of 0.2 mg/ml SM and stained with
Annexin V-FITC and propidium iodide. Cells positive for Annexin V-FITC were
considered apoptotic and dead cells were positive for propidium iodide staining. (A) The
percentage of healthy (viable, non-apoptotic), apoptotic, and dead cells are represented as
the mean ± standard error of six separate experiments. (B) The table lists the values that
correspond with the graph above. P values < 0.05 are indicated by an asterisk (*).
Figure 6 . Expression levels of select bcl-2 family proteins in Panel cells. Western blot
analysis of Bad, Bax, Bcl-2, and B c1-xl expression from total cell lysates in Panel cells
following treatment with 100 nM gemcitabine and/or 0.2 mg/ml SM. The presence of
/3-actin was used for normalization of results. The figures are representative of three
independent experiments with similar results.

Figure 7. Expression levels of select bcl-2 family proteins in treated Panel cells.
Levels of Bax, Bad, Bcl-2, and B c1-Xl in Panel cells were determined by western blot
analysis. Bands were quantified using the TotalLab software, normalized to /3-actin,
and expressed as values relative to protein levels in the untreated cells. Changes in
expression in SM and gemcitabine treatments as individual agents were evaluated
against the untreated, and the combination treatment was compared to gemcitabine.
P values < 0.05 are noted with an asterisk (*). (A) The ratio of protein to /3-actin
expression is representative of the mean ± standard error from > 3 independent
experiments. (B) The table lists the values that correspond with the graph. ND = not
detected.
Figure 8 . Analysis of selected bcl-2 family gene expression in Panel cells. RNA
extracted from Panel cells treated with 100 nM gemcitabine in the absence and
presence of 0.2 mg/ml SM was examined by RT-PCR arrays. (A) The graph shows the
fold change in Bad, Bax, Bcl-2, and B c I- x l gene expression normalized to untreated
Panel cells in three separate experiments. Values greater than 2 require further
investigation. (B) The table summarizes the average ACt values from separate
experiments. P values < 0.05 are indicated by an asterisk (*).
Figure 9. Analysis of apoptosis related gene expression in Panel cells. Panel cells were
treated with 100 nM gemcitabine and/or 0.2 mg/ml SM for 4 days. RNA was isolated
and apoptosis related genes were analyzed with RT-PCR arrays. The figure summarizes
the fold change in gene expression normalized to untreated Panel cells in three separate
experiments.
Figure 10. Cell cycle distribution of Panel cells. Panel cells were treated with 100 nM
gemcitabine alone and in combination with 0.2 mg/ml SM for 4 days. Cells were fixed,
stained with propidium iodide, and analyzed by flow cytometry. (A) The figure is
representative of data obtained from > 3 independent experiments with similar results.
(B) The table expresses values characteristic of Panel cell cycle as observed in separate
experiments. P values < 0.05 are indicated by an asterisk (*).
Figure 11. Comparison of /3-galactosidase activity in Panel cells treated with
gemcitabine in the presence and absence of SM. Panel cells were incubated in the
presence of C 12-FDG, gemcitabine and/or SM for 4 days. Cells were analyzed by flow
cytometry and mean channel fluorescence was determined. Treated cells were
normalized to the untreated. The figure is representative of three independent
experiments with similar results.
Figure 12. Western blot analysis of proteins associated with senescence in Panel cells.
Expression of Rb, pi 6 , and p21 in Panel cells in total cell lysates was determined by
western blot analysis. /3-actin was used as an internal control. The figures are
representative of triplicate experiments with similar results.
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Figure 13. Quantification of senescence related proteins in treated Panel cells. Total
cellular levels of Rb, p i 6 , and p21in Panel cells treated with 100 nM gemcitabine and/or
0.2 mg/ml SM were determined by western blot analysis. Bands were quantified by the
TotalLab software and were normalized to /3-actin. P values < 0.05 are noted with an
asterisk (*). (A) The ratio of protein to /3-actin expression was determined and
normalized to the untreated from three independent experiments. (B) The table lists the
values that correspond with the graph. ND = not detected.
Figure 14. Flow cytometric analysis of viability and /3-galactosidase activity in Panel
cells following Cs-ceramide treatment. Cells were treated with Cs-ceramide for 4 days
in the presence of C 12-FDG for the identification of senescent cells. Viability was
determined by propidium iodide staining (□) and senescence by /3-galactosidase
activity (o). The figure is representative of three independent experiments with similar
results.
Figure 15. Proposed model for the involvement of ceramide in cell cycle control. The
level of ceramide in the cell is proposed to determine whether a cell progresses through
the cell cycle, enters senescence, or initiates apoptosis. During the cell cycle, ceramide
levels increase until the restriction point in Gi. Cell cycle progression occurs when
ceramide levels are low, senescence when levels are moderate, and apoptosis when levels
are high.
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INTRODUCTION
In the United States, pancreatic cancer is currently the fourth leading cause of
cancer deaths in the United States, even though it is the eighth most common
(http://www.cancer.gov/statistics). Because pancreatic cancer is very aggressive, is
usually detected at an advanced stage, and does not respond well to chemotherapy or
radiation, treatment options are limited (McKenna and Eatock 2003). Due to the
involvement of local anatomical structures (i.e., the aorta), surgery is not an option for a
significant number of patients. Even with surgery, less than 5% of patients have a life
expectancy of greater than 5 years.
Since surgery has limited utility, greater focus is placed on systemic treatments
for this type of cancer. These treatments rarely provide more than relief of some of the
symptoms associated with the cancer, such as weight loss, pain, nausea, and anemia
(Shirota, Haji et al. 2005). The nucleoside analog gemcitabine [2’,2’-difluoro-2’deoxycytidine], is the front line chemotherapeutic treatment for pancreatic cancer
(Lawrence, Davis et al. 2001; Xiong, Rosenberg et al. 2004). It is taken up by the cell,
where it is phosphorylated to difluorodeoxycytidine triphosphate (dFdCTP). By
competing for DNA polymerase and ribonucleotide reductase, gemcitabine exposure
results in decreased intracellular dNTPs, inhibition of DNA synthesis, and subsequent
arrest of the cell cycle in S phase (Hui and Reitz 1997; Sun, Urrabaz et al. 2002). The
decreased amount of dCTP within the cell can also increase the possibility of
gemcitabine-triphosphate becoming incorporated in the DNA strand and, consequently
stop the synthesis of DNA. Presently, gemcitabine has proved to be the best option for
these patients, whether it is given alone or in combination with other treatments (Berlin,

Catalano et al. 2002; Bold, Chandra et al. 1999; Colucci, Giuliani et al. 2002; Xiong,
Rosenberg et al. 2004). Unfortunately, even with gemcitabine treatment, the average
survival time for patients with metastatic pancreatic cancer continues to be less than 6
months.

Apoptosis
Apoptosis, or programmed cell death, is a beneficial cellular process that takes
place in response to various conditions (Ghobrial, Witzig et al. 2005; Ricci and Zong
2006; Westphal and Kalthoff 2003). These include regulation of normal cell number,
some immune responses, and elimination of cells with irreparable DNA damage. When a
cell undergoes apoptosis, specific proteases and nucleases are activated, leading to
membrane blebbing, cell shrinking, condensation of chromatin, and nuclear
fragmentation. As apoptosis progresses, cellular DNA is cleaved and phosphatidylserine
moves from the inner to the outer leaflet of the plasma membrane. These changes allow
macrophages to identify and remove apoptotic cells without releasing the cellular
contents, thus avoiding an inflammatory response.
Apoptosis can occur through one of two pathways: 1) the extrinsic or membrane
receptor pathway and 2) the intrinsic or mitochondrial pathway. Both of these pathways
are interconnected and the members of one pathway will influence the other. Apoptosis
is further regulated through additional protein interactions, including caspases, bcl-2
family proteins, and inhibitor of apoptosis proteins (IAPs).
Whether the signal for a cell to undergo apoptosis is the result of the intrinsic or
extrinsic pathway, the pathways converge and result in the activation of a set of
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sequence-specific proteases (caspases), which are present within the cell as inactive
zymogens (procaspases) (Broker, Kruyt et al. 2005; Chang and Yang 2000; Ghobrial,
Witzig et al. 2005). To date, 14 different caspases are known in mammals, and are
divided into three groups depending on their function. Caspase 8, caspase 9, and
caspase 10 are referred to as initiator or apical caspases and are activated by
oligomerization. These caspases initiate the apoptotic pathways by activating
downstream caspases (caspase cascades). Caspase 3, caspase 6 , and caspase 7 are known
as effector or executioner caspases. Once activated, effector caspases are responsible for
cleaving cellular proteins irrespective of the apoptotic signal. The third group of caspases
is composed of caspase-1, -4, -5, -11, -12, -13, and -14 and is associated with cytokine
activity. The activation of caspases stops DNA replication and repair, and inactivates
anti-apoptotic proteins. Caspases also act on the cytoskeleton and the nuclear lamina of
the cell, resulting in the organized fragmentation of the cell and its organelles.
The extrinsic pathway is initiated as a result of the conditions present outside the
cell (Broker, Kruyt et al. 2005; Ghobrial, Witzig et al. 2005; Johnstone, Ruefli et al.
2002; Ricci and Zong 2006). Activation of the extrinsic pathway requires the binding of
extracellular ligands to receptors of the tumor necrosis factor family on the plasma
membrane. After the ligand binds to the receptor, caspase 8 and caspase 10 bind to form
the DISC (death-inducing signaling complex), ultimately resulting in the activation of
downstream caspases. The extrinsic pathway is regulated by inhibitors of apoptosis
proteins and c-FLIP.
The intrinsic pathway of apoptosis is initiated when damage is present inside of
the cell (internal signaling). These stresses include damage to DNA, the presence of
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reactive oxygen species (ROS), viral infection, and oncogene activation. Ultimately, this
pathway involves the release of pro-apoptotic proteins from the mitochondria which
initiate the caspase cascade via caspase 9 activation.
The intrinsic pathway is regulated by the bcl-2 protein family, whose presence
or absence regulates mitochondrial membrane permeability and the release of
apoptogenic factors from the mitochondria (Adachi and Imai 2002; Ghobrial, Witzig et
al. 2005). The members of this protein family are divided into groups based on which of
the four bcl-2 homology (BH) domains are present. All four BH domains (BH1-4) are
present on the anti-apoptotic members of the bcl-2 family, which include Bcl-2, Bcl-xL,
Mcl-1, Bfl-l/Al, Bcl-W and Bcl-G. The pro-apoptotic members lack the BH4 domain
and include Bax, Bak, Bok, Bik, Bim, Bcl-xs, Krk, Mtd, Nip3, Nix, Noxa, Bcl-B.
Members of the bcl-2 family containing only BH3 domains include Bid, Bad, Bim,
Puma, Noxa, and Bmf and influence the process of apoptosis by either inhibiting antiapoptotic or activating pro-apoptotic members (Ricci and Zong 2006; Westphal and
Kalthoff 2003).
Bak and Bax are both pro-apoptotic members of the bcl-2 family normally found
in the cytosol as monomeric proteins (Jia, Macey et al. 1999). Activation of the intrinsic
pathway causes Bax and Bak to translocate to the outer membrane of the mitochondria
(Kim, Emi et al. 2006; Lee, Hosotani et al. 1999). At the mitochondria, these proteins
will interact with a voltage-dependent anion channel (VDAC)/adenine nucleotide
translocator (ANT) complex, thus allowing for the formation of the mitochondrial
transition pore (PTP) and resulting in the loss of mitochondrial membrane potential
(MMP). This allows for the release of cytochrome c, Smac/DIABLO, and Omi/HrtA2
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from the mitochondria (Shimizu, Narita et al. 1999). Once in the cytoplasm,
Smac/DIABLO and Omi/HrtA2 will block the function of the inhibitors of apoptosis
proteins. Meanwhile, cytochrome c binds to apoptotic protease activating factor 1
(Apaf-1), thus enabling it to engage procaspase-9 to form the protein complex called the
apoptosome, activate caspase 9, and propagate the caspase cascade (Broker, Kruyt et al.
2005; Johnstone, Ruefli et al. 2002).
The presence of anti-apoptotic Bcl-2 and Bcl-xLconfer protection to the
mitochondria by heterodimerizing with Bak and Bax (Oltvai, Milliman et al. 1993).
Bcl-2 is found predominantly on the outer mitochondrial membrane, but also in the
endoplasmic reticulum and the nuclear envelop, while B c1-Xl is normally located in the
cytosol (Lee, Hosotani et al. 1999). Although expression levels alone do not determine
their function, both Bcl-2 and Bcl-xLover-expression alter mitochondrial membrane
permeability by blocking the formation of the transition pore. This limits the release of
pro-apoptotic proteins, such as cytochrome c, from the mitochondria, consequently
inhibiting apoptosis (Fleischer, Ghadiri et al. 2006; Yang, Liu et al. 1997). In addition,
B c1-Xl

inhibits caspase activation by interacting with Apaf-1, which prevents the

formation of the apoptosome (Scorrano and Korsmeyer 2003).
Bad is a pro-apoptotic protein normally found in its inactive form and bound to
14-3-3 scaffold proteins in the cytosol, which prevents Bad from accessing Bcl-2 and
Bc1-xl in the mitochondria (Hashimoto, Hirose et al. 2005; Zha, Harada et al. 1997).
Déphosphorylation of the serine residues activates Bad and detaches it from the scaffold
proteins (Adachi and Imai 2002; Ayllon, Martinez et al. 2000; Kitada, Krajewska et al.
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1998). This enables Bad to move to the mitochondria where it heterodimerizes and
inactivates anti-apoptotic proteins, Bcl-2 and B c1-xl, thereby promoting apoptosis.

Sphingolipids
Ceramide is an intracellular second messenger involved in apoptosis, senescence,
cell cycle, cell differentiation, and growth arrest (Ogretmen 2006; Ruvolo 2003).
Cellular stresses, including the presence of cytokines of the TNF family, environmental
stress (heat shock), withdrawal of growth factors, radiation (ionizing or UV), and
chemotherapeutics, cause ceramide accumulation in the cell. Although the details are not
yet clear, it is believed ceramide may function as a “biostat” by measuring and indicating
cellular stress. Ceramide affects a number of signaling proteins including cathepsin D,
ceramide-activated protein phosphatases (CAPPs), which include PP1 and PP2A,
ceramide-activated protein kinase (CAPK, also known as kinase suppressor of Ras),
MAPK, RAF-1, PKC^, and MEKK (Perry and Hannun 1998). Due to the variety of
important regulatory proteins ceramide may interact with, it is able to function as a
pro-apoptotic signal in both the intrinsic and extrinsic pathways of apoptosis.
Ceramide levels are governed by the rates of formation (de novo synthesis and
activity of sphingomyelinases) and degradation. De novo ceramide synthesis is initiated
on the cytosolic face of the endoplasmic reticulum with the condensation of serine and
palmitoyl coenzyme A to yield sphinganine (Perry and Hannun 1998; Pettus, Chalfant
et al. 2002). This is followed with acylation and dehydrogenation to form ceramide
(Figure 1). Once formed, ceramide is transported to the Golgi by the ceramide transfer
protein (CERT) where it is used in the synthesis of sphingomyelin and

13

glycosphingo lipids. Through the action of sphingomyelin synthase, phosphatidylcholine
(PC) transfers a phosphocholine headgroup to ceramide, forming sphingomyelin (SM)
and diacylglycérol (DAG). De novo synthesis can be stimulated by Fas and some
chemotherapeutics (e.g. Dox).
Sphingomyelinases (SMases) hydrolyze SM to generate ceramide (Perry and
Hannun 1998; Ruvolo, Clark et al. 2002). To date, several SMases have been identified
and are recognized by their pH optima and location in the cell. Acid sphingomyelinase
(aSMase) is located primarily in lysosomes and, to a lesser extent, in caveoli or lipid rafts
in the plasma membrane, while neutral sphingomyelinase (nSMase) is found in the
plasma membrane, microsomes, Golgi, and mitochondria (Mathias, Pena et al. 1998;
Pettus, Chalfant et al. 2002).
Additional bioactive lipids are generated from the hydrolysis of ceramide
by ceramidases (CDases) to yield sphingosine or by ceramide kinase to yield
ceramide-I-PO4 (C1P) (Mathias, Pena et al. 1998; Ruvolo, Clark et al. 2002). In turn,
sphingosine can be phosphorylated by sphingosine kinases (SKI and SK2) to produce
sphingosine 1-phosphate (SIP). Furthermore, SIP can be dephosphorylated by SIP
phosphatases to regenerate sphingosine or it can be cleaved by SIP lyase to produce
ethanolamide- 1-phosphate.
Ceramide levels influence the release of pro-apoptotic proteins from the
mitochondria (Perry and Hannun 1998; Ruvolo 2003; Siskind 2005). The presence of
excess ceramide in the mitochondria causes the activation of PP2A. Activation of PP2A
leads to the inactivation of anti-apoptotic Bcl-2 and PKCa; resulting in mitochondrial
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depolarization, the release of cytochrome c, and the activation of the apoptosome (Lee,
Hannun et al. 2000; Ruvolo, Deng et al. 1999; Zhang, Liu et al. 1997).
The enzymes necessary for ceramide production (de novo and via SMases) are
formed in different subcellular compartments and may determine the signaling pathway
that is activated (Mathias, Pena et al. 1998). For instance, treating cells with exogenous
bacterial SMase promotes the cleavage of SM to generate ceramide but does not lead to
apoptosis. Thus it can be concluded that SM pools located on the outer leaflet of the
plasma membrane are not used as sources of ceramide for apoptosis (Linardic and
Hannun 1994). However, targeting bacterial SMase to different cellular compartments,
via the introduction of protein localization signals within bacterial SMase, induced
apoptosis only when the enzyme was targeted to the mitochondria. In addition, ceramide
generated via the de novo pathway in the mitochondria has also been associated with
apoptosis induction after chemotherapy exposure (Birbes, El Bawab et al. 2001).
Studies have shown the levels of SM in tumor cells differ from those of normal
cells (Dyatlovitskaya 1998; Kandyba, Kobliakov et al. 2004). One hypothesis is that
tumor cells are unable to initiate apoptosis due to a lack of sufficient SM which limits
ceramide levels in the cell. Since ceramide is necessary for apoptosis signaling, tumor
cells can bypass the process. Thus, it has been postulated that rational manipulation of
ceramide levels will lead to enhanced efficacy.

Senescence
Cellular senescence is one response of cells to the presence of DNA damage
(Campisi 2000; Dimri 2005; Kahlem, Dorken et al. 2004; te Poele, Okorokov et al.

15

2002). Senescent cells are characterized by their flattened appearance, enlarged size and
increased cytoplasmic granularity due to an increase in the presence of vacuoles. These
changes are accompanied by alterations in gene expression, protein processing, and
metabolism. One of the characteristic indicators of senescence is an increase in
senescence-associated /3-galactosidase activity, which is thought to be the result of greater
lysosomal mass in the cells.
Because senescent cells are present in cell cycle arrest (Go), they are unable to
synthesize DNA (Dimri 2005; Kahlem, Dorken et al. 2004; Schmitt 2007; Venable, Lee
et al. 1995). These cells remain viable, though mitotically inactive. It is important to
note that these cells will continue to be metabolically active and may produce proteins
that stimulate tumor activities, such as growth factors, cytokines, and metalloproteases.
However, once cells become senescent, they may be unable to enter into apoptosis even if
they are exposed to apoptosis-inducing agents.
There are two types of senescence: Replicative and premature. Replicative
senescence presumably limits a cell’s ability to proliferate and is initiated as a result of
telomere shortening due to normal replication (Ben-Porath and Weinberg 2004; d'Adda di
Fagagna, Reaper et al. 2003; Kahlem, Dorken et al. 2004; Shay and Wright 2005).
Telomeres are the repetitive DNA sequences whose function in the cell is to protect the
ends of the chromosomes. Conversely, the induction of premature senescence can come
about as a result of DNA damage generated from physiological stresses (Lloyd 2002).
Although initially reversible, premature senescence may be irreversible through unknown
mechanisms (Beausejour, Krtolica et al. 2003). Irrespective of the stress signal, both the
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p53 and retinoblastoma (Rb) tumor suppressor genes are associated with senescence
induction (Shay, Pereira-Smith et al. 1991).
Rb regulates cell proliferation by controlling progression through the Gi
restriction point of the cell cycle. Rb is normally inactive as a result of cyclin dependent
kinases (CDKs), which maintain Rb in a phosphorylated state (Campisi 2001). These
CDKs are inhibited by pi 6 , p21, and p27, which are often up-regulated in senescent cells
(Bringold and Serrano 2000; Roninson 2003). As a result, senescent cells will express
active Rb which inhibits the genes involved in cell-cycle progression. However, if Rb is
inactivated, cells will re-initiate cell cycle progression and come out of senescence.
Through in vitro studies using the Panel human pancreatic cancer cell line, the
effects of exogenously administered SM in combination with gemcitabine were examined
with respect to the enhancement of the apoptotic effects. However, during the course of
this work, the focus of the study was expanded to include senescence.
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MATERIALS AND METHODS
Cell Culture
The human pancreatic cancer line Panel was obtained from Dr. David Gold
(Garden State Cancer Center, Belleville, NJ) and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) (Irvine Scientific, Santa Ana, CA) containing 10% fetal
bovine serum (Hyclone Laboratories, Logan, UT), 1% Penicillin-StreptomycinGlutamine (Gibco, Grand Island, NY), 1% non-essential amino acids (Irvine Scientific),
and 1% sodium pyruvate (Irvine Scientific). The cells were maintained at 37 °C with
5% C 02.

Preparation of SM
SM liposomes were generated following published protocols (Modrak, Rodriguez
et al. 2002; Modrak, Cardillo et al. 2004). Egg yolk SM (Avanti Polar Lipids, Alabaster,
AL) was prepared as a 100 mg/ml suspension in PBS (4.3 mM KH 2 PO 4 , 1.4 mM
Na2HP04 , 137 mM NaCl, 2.7 mM KC1) and sonicated for 10 minutes in a warm water
bath. The suspension was subsequently passed through 1.0 and 0.1 pm filters with the
Avanti Mini-Extruder.

Cell Viability Assay
Cell viability assays were performed using the MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) (Sigma-Aldrich, St. Louis, MO) quantitative
colorimetric assay for mammalian cells (Mosmann 1983). Panel cells were harvested
using trypsin (Irvine Scientific) and seeded in 96-well plates at 2000 cells/well.
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Approximately 24 hours after plating, cells were treated with gemcitabine (Eli Lilly,
Indianapolis, IN), SM, or a combination of gemcitabine and SM. Plates were incubated
for 4 days (approximately four doublings). Media was removed from wells and replaced
with a 0.5 mg/ml MTT in DMEM without additives. After 2-4 hours, the MTT solution
was removed and the cells were solubilized with DMSO. Plates were read at A570 on a
SpectraMax 250 Microplate Reader (Molecular Devices, Sunnyvale, CA). Data was
normalized to untreated cells and values were multiplied by 100% to determine the
percent of viable cells.

SM Uptake
Panel cells were seeded in 6 -well plates at 2000 cells/well and allowed to adhere
overnight. The media and unattached cells were removed and the cells were treated with
0.5, 0.2, or 0.1 mg/ml [3H-methyl]choline-SM (American Radiolabeled Chemicals,
St. Louis, MO) at a specific activity of 1501.6 dpm/nmole SM or 0.5, 0.2, or 0.1 mg/ml
unlabeled SM. At 0, 4, 24, 48, 72, and 96 hours post-treatment, media was removed,
wells were washed three times with IX PBS, and cells were solubilized with 1% sodium
dodecyl sulfate (Sigma-Aldrich) in water. Samples containing [ H-methyl]choline-SM
were transferred to scintillation vials containing 10 ml Ecoscint (National Diagnostics,
Atlanta, GA) and radioactivity was determined by using a Liquid Scintillation Analyzer
(Packard Instrument Company, Downers Grove, IL). Identically treated, but nonradioactive, samples were analyzed by spectrophotometry at A260 and A280 to determine
protein concentration using the formula: protein (mg/ml) = 1.56 (A280) - 0.7363 (A260).
This equation is from the nomograph prepared by E. Adams (distributed by the California
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Corporation for Biochemical Research, Los Angeles 63, CA), which was based on the
extinction coefficient for enolase and nucleic acid (Warburg and Christian 1942).

Analysis o f Apoptosis
Throughout the course of this study, Panel cells were treated in the presence of
gemcitabine at the IC5o and/or SM at the ICio for 4 days before harvesting for subsequent
analyses. Panel cells to be left untreated or treated with SM were seeded at 0.5 x 106
cells/flask while cells to be treated with gemcitabine or a combination of gemcitabine and
SM were seeded at 106 cells/flask and allowed to adhere overnight. The media was
replaced with treatment media containing 100 nM gemcitabine, 0.2 mg/ml SM, or a
combination of the two and the cells were incubated in treatment for 4 days before
processing.
Apoptosis was measured with Annexin V-propidium iodide staining and
subsequent flow cytometry (Vermes, Haanen et al. 1995). Cells were harvested by
scraping and combined with non-adhered cells present in the culture media. The cells
were washed with PBS and pellets were resuspended in 250 pi IX binding buffer
(10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCh). Five microliters of
Annexin V-FITC (BD Biosciences Pharmigen, San Diego, CA) and 10 pi propidium
iodide (Sigma-Aldrich) solution (50 pg/ml stock), were added directly to tubes. Samples
were allowed to stand at room temperature, in the dark, for 15 minutes. Immediately
before analysis, the samples were diluted with 1.5 times volume PBS. Fluorescence was
measured using the Becton-Dickenson FACSCaliber (BD Bioscience Pharmigen). Using

20

the CellQuest Software, apoptotic cells were identified as being Annexin V-FITC
positive while non-viable cells were distinguished by propidium iodide staining.

Preparation of Protein Cell Lysates and Western Blot Analysis
Cells (both adhered and non-adhered) were harvested by scraping, collected at
500 x g for 5 minutes, and washed once with PBS. Cell pellets were resuspended in 1 ml
PBS and transferred to eppendorf tubes. Samples were centrifuged at 500 x g and pellets
were resuspended in deionized water. A 10% sodium dodecyl sulfate solution was added
to samples for a final concentration of 1% SDS. Each sample was drawn through an
insulin syringe to lyse and shear DNA. All cell lysates were stored at -80 °C.
The concentration of total protein was estimated by spectrophotometry at
A26o/A280- For each sample, 20 pg total protein was heated in sample buffer (final
concentration was 70 mM sodium dodecyl sulfate, 60 mM TrisCl, pH 8.0, 100 mM
glycerol, 40 mM 2-mercaptoethanol, and trace bromophenol blue) for 5 minutes at 95 °C.
The samples were separated on 4-20% SDS gradient gels (Life Therapeutics, Frenchs
Forests, Australia) using a Tris-HEPES-SDS running buffer (Life Therapeutics).
Proteins were transferred to polyvinylidene fluoride (PVDF) microporous membranes
(Millipore, Bedford, MA) for 90 minutes at 40 V. Membranes were blocked overnight
at 4 °C with Superblock Blocking Buffer (Pierce, Rockford, IL) containing 0.05%
Tween-20 (JT Baker, Phillipsburg, NJ). Antibodies for /3-actin (Sigma-Aldrich), Bad,
Bax, Bcl-2, B c1-Xl, pi 6, p21, and Rb (BD Biosciences Pharmigen) were used to probe
blots for 1 hour at room temperature. Blots were washed in Tris buffered saline (20 mM
TrisCl, pH 7.5, 100 mM NaCl) four times for 20, 10, 10, and 10 minutes respectively,
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followed by a 30 minute incubation with horseradish peroxidase conjugated anti-mouse
or anti-rabbit IgG antibody (Rockland Immunochemicals, Gilbertsville, PA). Blots were
washed a second time, as before. SuperSignal chemoluminescent substrate (Pierce) was
used to visualize protein expression. Images were analyzed using the TotalLab software
(Nonlinear Dynamics Ltd, Durham, NC) and data was normalized to (3-actin.

RNA Isolation
Total RNA was isolated with Trizol (Gibco, BRL) (Ausubel and Seidman 1988).
Cells (both adhered and non-adhered) were harvested by scraping, collected at 500 x g
for 5 minutes, and washed once with PBS. Pellets were resuspended in PBS and
transferred to RNase free tubes. Samples were centrifuged and PBS was removed. The
cells were disrupted by the addition of 1 ml Trizol and incubated at room temperature for
5 minutes. One fifth volume chloroform was added and the tubes were vigorously
shaken by hand, incubated for 3 minutes, and centrifuged at 20,800 x g for 15 minutes.
The aqueous phase was transferred to new RNase free tubes and isopropanol was added
to each sample at 0.5 the original volume of Trizol per tube. Samples were incubated at
room temperature for 10 minutes, centrifuged at 20,800 x g for 10 minutes and the
supernatant removed. Pellets were washed once with 75% ethanol. Excess ethanol was
removed by air drying and samples were stored at -80 °C.
RNA pellets were resuspended in DEPC H2O and re-purified using the RNeasy
Mini Kits (Qiagen, Valencia, CA) according to the supplied protocol. Prior to loading
the columns, samples were treated with RNase-free-DNase (BD Biosciences Pharmigen)
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for 15 minutes to remove DNA contamination. Samples were eluted from the columns
with 30 pi RNase-free water.
RNA quantity and quality were determined by measuring optical density at 260
and 280 nm using spectrophotometry. RNA concentration was calculated as 1 OD260 is
equivalent to 40 pg/ml RNA. The quality of RNA was established by determining the
ratio of absorbance at 260 and 280 nm and examined by denaturing (formaldehyde)
agarose gel electrophoresis.

First-strand cDNA Synthesis
The Brilliant SYBR Green QPCR Core Reagent Kit (Stratagene, La Jolla, CA)
was used to generate cDNA from purified RNA as per manufacturer’s instructions. For
each reaction, 5 pg RNA in DEPC H2O was primed with oligo(dT)2o. Samples were
heated to 65 °C for 5 minutes and subsequently allowed to slowly cool to 37 °C for
10 minutes. A reaction mix containing dATP, dCTP, dGTP, dTTP, StrataScript buffer,
RNase Block Ribonucléase Inhibitor, and StrataScript reverse transcriptase was prepared
and added according to the Stratagene first-strand cDNA synthesis protocol supplied with
the reverse transcriptase. Samples were incubated at 42 °C for 1 hour and the reaction
was stopped by heating to 95 °C for 5 minutes. Samples were stored at -20 °C.

Real-time Quantitative PCR (QPCR)
Human Apoptosis RT Profiler™ PCR Arrays (SuperArray Bioscience
Corporation, Frederick, MD) were used to amplify cDNA with the Brilliant SYBR®
Green QPCR Core Reagent Kit (Stratagene). As per manufacturer’s instructions, a
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master mix consisting of IX core buffer, 4 mM MgCh, 0.8 mM dNTP mix, 8% glycerol,
3% DMSO, 30 nM reference dye, 0.167X SYBR Green, and 1.25 Units Taq DNA
polymerase was prepared. A total of 5 pg cDNA sample was added to the master mix for
a final concentration of 50 ng cDNA per reaction (25 pi final volume per reaction).
Equal amounts of the sample mixture were then added to the wells of the microarray
which contain the primer sets for specific genes involved in apoptosis. Using the
Mx3000P® QPCR System (Stratagene), samples were subjected to an initial denaturation
cycle of 10 minutes at 95 °C; 40 cycles of 30 seconds denaturation at 95 °C; 1 minute
annealing at 50-60 °C; 1 minute elongation at 72 °C.
The Ct, or threshold cycle, for each reaction was determined by the QPCR
software. The average Ct of both GAPDH and /3-actin was used to normalize expression.
The fold change in gene expression between untreated and treated Panel was calculated
as 2 l'AACt|. A fold change greater than 1 corresponded to a “-fold up-regulation” and a
change less than 1 was reported as the negative inverse (i.e. “-fold down-regulation”).

Cell Cycle Analysis
Cell cycle distribution was analyzed by propidium iodide staining (Noguchi
1998). Panel cells were harvested by scraping, washed, and resuspended in 0.5 ml PBS.
The cells were fixed by adding 4.5 ml of 70% EtOH and refrigerated overnight. Cells
were collected by centrifugation (200 xg, 5 minutes) and washed once with PBS. The
cell pellet was resuspended in propidium iodide staining solution (0 . 1% (v/v)
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Triton X-100 in PBS, 0.2 mg/ml DNAse-free RNase A, and 20 pg/ml propidium iodide).
Samples were incubated for 15 minutes at 37 °C and DNA content was analyzed by flow
cytometry.

Senescence Detection (¡3-galactosidase Activity)
Senescent cells were identified by examining /3-galactosidase activity using
C 12-FDG (lipophilic fluorescein-di-/3-D-galactopyranoside). In senescent cells, the
presence of /3-galactosidase results in the cleavage of galactose from FDG, leaving the
fluorescent molecule associated with the cellular membrane. Panel cells were seeded at
10,000 cells/well in 24-well plates and allowed to adhere overnight. The media in each
well was replaced with drugs at varying concentrations in the presence of 5 pM C 12-FDG.
Plates were incubated for 4 days at 37 °C with 5% CO2. Cells were harvested using
2 mM EDTA in PBS and centrifuged at 500 x g for 5 minutes. Pellets were resuspended
in 250 pi PBS plus 5 pg/ml propidium iodide and analyzed by flow cytometry.

Statistical Analysis
All data has been expressed as mean ± standard deviation. Student’s t-tests were
used to determine statistical significance. Only statistically significant P values
(P < 0.05) were reported. Calculation of combination index (Cl) was used to determine
synergy (Chou and Talalay 1984). The Cl values were calculated by determining the
percentage of cell growth inhibited by gemcitabine and SM individually and in
combination using the formula: Cl = (Dj/Dxi) + (D2/DX2) + (D 1D2/DX1DX2), where Dx is
the IC50 for an individual drug, D is the IC50 for an individual drug in the combination
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treatment, and the subscripts 1 and 2 refer to gemcitabine and SM, respectively.
Synergism is defined as Cl < 0.9, additivity as 0.9 < Cl < 1.1 and antagonism as Cl > 1.1.
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RESULTS
Panel cells exhibit an increased chemosensitivity to gemcitabine treatment in the
presence of SM.
To determine whether exogenous SM can increase chemosensitivity, Panel cells
were treated with SM alone for 4 days to assess treatment sensitivity. The effect of the
treatment on the metabolic viability of the cells was determined using the MTT assay. A
dose response profile was generated and the concentrations needed to inhibit cell growth
by 50% (IC50) for SM was determined to be 1.2 mg/ml and the IC 10 ( 10% growth
inhibition) was 0.2 mg/ml (data not shown).
The effects of gemcitabine alone and in combination with 0.2 mg/ml SM on
Panel were examined by the MTT assay (Figure 2). The IC50 for gemcitabine decreased
from 78.3 ± 13.7 nM to 13.0 ± 3.0 nM with the inclusion of SM in the treatment
(P < 0.001). A Cl value of 0.36 indicated a synergistic effect between gemcitabine and
SM in Panel cells. It is also noteworthy that even at the highest doses of gemcitabine
approximately 35% of the cells continued to be viable. With the addition of SM, < 10%
of the cells remained viable at the highest concentrations.

Uptake of Exogenous SM in Panel Cells Increases Over Time.
To determine if Panel cells can internalize exogenously administered SM, cells
were exposed to 0.5, 0.2, or 0.1 mg/ml [3H-methyl]choline-SM or non-labeled SM and
aliquots of cells were analyzed at 0, 24, 48, 72, and 96 hours post-treatment. Samples
treated with labeled SM were subjected to liquid scintillation analysis to determine the
amount of [ H-methyl]choline-SM present in the cells. Cells treated with non-radioactive
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SM were used as a control for normal cell proliferation by determining total protein
concentration at the given time points.
The amount of SM taken up by the cells was normalized to total protein levels.
Results showed that by 48 hours, > 200 nmole SM (19.0 %) was taken up per mg protein
in the presence of 0.5 mg/ml SM, 100 nmole (29.6 %) SM/mg protein with 0.2 mg/ml
SM, and 20 nmole (13.8 %) SM/mg protein with 0.1 mg/ml SM (Figure 3). Thus it was
concluded that Panel cells will incorporate greater amounts of SM with increasing
concentrations. At the ICio of SM, a significant increase in SM was taken up by the cells,
which peaked at 48 hrs post-treatment.

Panel cells treated with a combination of gemcitabine and SM have increased
apoptosis.
Apoptosis is a major pathway for the induced death of cells. To determine the
percentage of cells undergoing apoptosis in response to treatment, Panel cells were
treated with 100 nM gemcitabine, 0.2 mg/ml SM, or a combination of gemcitabine and
SM for 4 days. The cells were stained with Annexin V-FITC and PI and analyzed by
flow cytometry to determine the cytotoxicity of the agents (Figure 4). Since the presence
of phosphatidylserine (PS) outside the cell increases during apoptosis, cells stained with
Annexin V-FITC, which is specific for PS, were considered to be apoptotic (Vermes,
Haanen et al. 1995). Cell death was monitored with propidium iodide, which is actively
effluxed in metabolically viable cells. The percentage of apoptotic Panel cells present
with no treatment, SM alone, gemcitabine alone, and the combination treatments was
3.4 ± 3.0%, 4.4 ± 3.3%, 38.9 ± 6.8%, and 48.4 ± 6.6%, respectively (Figure 5). Both the
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untreated and SM treatment groups exhibited a relatively equal percentage of apoptotic
cells, which supports the idea that SM alone will not cause the cells to undergo apoptosis.
Cells treated with gemcitabine at the IC50 show significant apoptosis and the presence of
SM enhanced the toxic effect resulting in an increase in apoptotic cells versus
gemcitabine alone.

Gemcitabine treatment causes a decrease in the expression of anti-apoptotic bcl-2
family proteins in Panel cells.
The effect of SM, gemcitabine, and combination treatment on the expression of
pro- and anti-apoptotic proteins in Panel cells was examined. Cells were treated as
previously described, total cell lysates were prepared, and Bad, Bax, Bcl-2, and B c1-xl
expression was determined by western blot analysis (Figure 6). These proteins were
investigated as a result of their importance in the regulation of apoptosis. /3-act in was
used as an internal control for each experiment. The relative image density of individual
bands was normalized to /3-actin and averaged over three experiments (Figure 7). Since
untreated Panel cells were used as the controls for normal protein expression, its value
was set to 1.0 .
The results indicated that treating Panel cells with SM as a single agent caused a
decrease in Bad expression and an increase in both Bcl-2 and B c1-xl. In the presence of
gemcitabine alone, there was a decrease in the relative levels of Bad, Bcl-2 and Bcl-xL.
Although, combination treatment of gemcitabine and SM decreased levels of both Bcl-2
and B c1-xl when compared to the untreated, these changes were not significantly
different from those observed with gemcitabine alone.
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The current understanding of apoptosis induction suggests that absolute levels of
bcl-2 family proteins alone are not sufficient for apoptosis induction, but the ratio of pro
to anti-apoptotic proteins may be more relevant (Breckenridge and Xue 2004; Strobel,
Swanson et al. 1996). Although our studies indicated the levels of pro-apoptotic proteins
decreased with gemcitabine and combination treatment groups, the levels of antiapoptotic proteins were significantly lower in comparison. The ratios of total anti- to
pro-apoptotic proteins were determined to be 1.47 with SM alone, 0.06 for gemcitabine
alone, and 0.04 for combination treatments. Together, our data suggest additional factors
are present to promote apoptosis in Panel cells.

Treatments alter the expression of genes associated with apoptosis.
To determine if the observed differences in protein expression of Panel cells in
response to treatment were associated with transcription changes, RT-PCR microarrays
were used. Panel cells were treated as before, RNA was isolated using Trizol, and gene
expression profiles were generated by normalizing individual genes to the GAPDH and
/3-actin housekeeping genes for each experiment. Relative changes in gene expression
were calculated using the AACt method. It should be stressed that these are preliminary
studies and that a comprehensive analysis of gene expression changes are outside the
scope of this thesis.
These results suggested that changes in expression for a number of bcl-2 protein
family genes were dependent on treatment. As shown in Figure 8, a 1.4-, 25.5-, 1.0-, and
13.2-fold increase (P < 0.5) in Bad, Bax, Bcl-2, and Bcl-xi gene expression, respectively,
was observed in Panel cells treated with SM alone. On the other hand, Bad and Bcl-2
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was down-regulated in Panel cells treated with gemcitabine alone. Of interest is that the
combination of gemcitabine and SM treatment also resulted in the down-regulation of
Bad, but causes Bcl-2 levels to return to that of untreated Panel.
The use of PCR arrays offered the opportunity to obtain additional information for
apoptosis-related gene expression (Figure 9). An up-regulation was seen in the
expression of Bak, caspase 8, caspase 10, and p53 binding protein when Panel cells
were exposed to SM treatment for 4 days. Gemcitabine alone down-regulated the genes
for caspase 3, caspase 8, caspase 10, F ADD, and p53 binding protein. By combining
SM with the gemcitabine, an increase in expression of these pro-apoptotic genes similar
to that of SM alone was seen. In the case of caspase 10, the increase in gene expression
was actually greater in the combination treatment than with SM alone. However,
caspase 3 expression decreased with the both single agent gemcitabine and the
combination treatment.

Analysis of cell cycle distribution in Panel treated cells.
By competing with DNA polymerase and ribonucleotide reductase, gemcitabine
serves to inhibit DNA synthesis, subsequently causing an arrest of the cell cycle at the
S phase. The cell cycle of Panel cells was analyzed to see how the treatment affected
cell cycle distribution (Figure 10). Cells were treated with 100 nM gemcitabine,
0.2 mg/ml SM, or a combination of the two agents for a total of 4 days, as before. The
cells were then fixed and stained with PI before cytometric analysis. Panel cells treated
with SM alone did not exhibit significant changes in cell cycle distribution compared to
the untreated, which confirmed that SM was non-toxic at the administered concentration.
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Treatment with gemcitabine alone resulted in 44.9% of the cells accumulating in sub-Gi
with a concomitant decrease in the number of cells in Go/Gi and G2/M phases. These
changes were accented in cells receiving a combination of gemcitabine and SM
treatment, where 57.4% of the cells accumulated in sub-Gi. These results indicate that
the combination treatment is able to alter the cell cycle in a synergistic manner.

Gemcitabine treatment increases fi-galactosidase activity in Panel cells.
Morphological changes consistent with senescence (i.e. large flat cells) were
observed in Panel cells receiving gemcitabine treatment. With the knowledge that
gemcitabine does not cause 100% of cells to undergo apoptosis and that an increase in
the size of cells treated with this agent is observed, we examined the possibility of
senescence involvement through the measurement of senescence-associated
/3-galactosidase activity.
By including Ci2-fluorescein-digalactoside (C 12-FDG) in the cell culture media of
Panel cells treated with gemcitabine and/or SM, senescence-associated /3-galactosidase
activity was examined. Cells expressing /3-galactosidase are able to cleave the C 12-FDG,
thus liberating the membrane-associated Ci2-fluorescein component which can be
detected by flow cytometry. Cells treated with gemcitabine alone exhibited a dose
dependent increase in senescence-associated /3-galactosidase activity, which was
approximately 4.5 fold greater than the combination treatment (Figure 11). However,
Panel cells treated with gemcitabine in the presence of SM exhibited nearly identical
levels of /3-galactosidase activity compared to untreated cells. This indicates that the
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inclusion of SM altered the viable-senescent-apoptotic distribution of cells after
gemcitabine treatment.

Expression o f Rb, p i 6, andp21 in Panel treated cells.
The role of senescence induction in gemcitabine-treated Panel cells was
examined by determining the expression levels of key cell cycle regulatory proteins.
Panel cells were treated, and protein cell lysates were prepared 4 days post-treatment, as
before, for western blot analysis of Rb, pi 6 , and p21 (Figure 12). The relative density of
each band was quantified and results were averaged over three experiments (Figure 13).
Panel cells treated with SM alone showed increased expression of both Rb and pi 6
(P < 0.001). As a single agent, gemcitabine decreased expression of Rb compared to
untreated cells and reduced p i 6 and p21 expression to undetectable levels. However,
cells treated with both agents did not exhibit statistically significant changes in Rb or p21
over gemcitabine alone whereas p i 6 was detected in this treatment group.

Cs-ceramide induces apoptosis and senescence in Panel treated cells
Chemotherapeutic treatments may cause cells to undergo senescence. Our studies
have shown that a combination of gemcitabine and SM results in increased apoptosis and
reduced senescence. Previous work demonstrated that gemcitabine activated aSMase and
increased ceramide formation (Modrak, Cardillo et al. 2004). In order to determine the
relation between senescence and apoptosis induction as a result of gemcitabine treatment,
Panel cells were treated with the water-soluble analog Cg-ceramide (N-octanoyl-Dsphingosine) in the presence of C 12-FDG. These cells were analyzed by flow cytometry
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for /3-galactosidase activity and cell viability using propidium iodide. Our results showed
that treatment of Panel cells with Cs-ceramide for 4 days resulted in dose dependent cell
death with the IC50 for Cg-ceramide being 43.2 ±2.1 pM while concentrations below
30 pM did not affect cell viability (Figure 14). However, changes were also observed in
senescence-associated /3-galactosidase activity (mean channel fluorescence), which
increased with ceramide concentration, reaching a maximum at 21.7 ± 1.5 pM and
decreasing at higher ceramide concentrations. These results indicate ceramide induces
both apoptosis and senescence in a concentration-dependent manner.
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DISCUSSION
Malignant tumors develop when cells undergo uncontrolled proliferation and
either lack the ability or are resistant to apoptotic stimuli (Gerhard, Schmid et al. 2002).
Numerous mutations in pancreatic cancers, including the presence of cell growth factors,
non-functional factors for growth inhibition, and mutated tumor suppressor genes,
interfere with the induction of apoptosis, impart generalized drug resistance, and,
ultimately, make treatments ineffective. Together, these factors dictate how the cancer
will develop, progress, and metastasize.
Sphingolipids have been shown to play a central role in apoptosis regulation
(Hannun 1996; Hannun and Obeid 2002; Itoh, Kitano et al. 2003; Ogretmen and Hannun
2001; Ogretmen and Hannun 2004). Ceramide serves as a secondary messenger by
interacting with kinases, phosphatases, and proteases. Agents causing cellular stress
affect the regulation of sphingo lipid metabolism and increase the amount of ceramide
present in the cell. Increased basal ceramide levels lead to chemosensitivity, while
reduced levels lead to chemoresistance (Hannun and Luberto 2000; Itoh, Kitano et al.
2003; Ogretmen and Hannun 2001). For instance, stimulators of de novo ceramide
synthesis (e.g., PSC-833), inhibitors of ceramidase [e.g., B13 or (IS, \R)-D-erythro-2(A-myristoylamino)-l-phenyl-1-propanol] and inhibitors of glycosylceramide synthase
(e.g., tamoxifen or DL-//zreo-l-phenyl-2-palmitoylamino-3-morpholino-1 -propanol)
increase ceramide and result in chemosensitivity (Samsel, Zaidel et al. 2004; Selzner,
Bielawska et al. 2001; Seumois, Fillet et al. 2007; Wang, Giuliano et al. 2002).
Generally, it has been observed that chemotherapeutic agents increase ceramide levels
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through SM hydrolysis primarily, but examples of chemotherapeutics increasing de novo
synthesis are known (Ogretmen and Hannun 2001).
Levels of biologically active sphingolipids and enzymes participating in
sphingolipid metabolism are altered in cancer cells though not in a predictable or uniform
manner (Modrak, Cardillo et al. 2004; Senchenkov, Litvak et al. 2001). We hypothesized
that chemoresistance in pancreatic cancer cells may be the result of insufficient levels of
the sphingo lipid, ceramide, which prevents apoptosis signaling. Furthermore, we
hypothesized that this was a result of inadequate intracellular SM substrate available to
the drug-activated SMases for conversion to ceramide. Thus, we postulated that
concomitant treatment with exogenous SM would allow the cells to enter into apoptosis
when treated with chemotherapeutic agents, in line with our previously reported results
with colonic and pancreatic cell lines (Modrak, Lew et al. 2000; Modrak 2004).
Pancreatic cancer is a particularly aggressive and drug-resistant disease for which
improvements in therapy are much needed. For this reason, we examined the use of
exogenous SM to enhance the effect of gemcitabine in pancreatic cancer cells. Previous
work demonstrated that gemcitabine activated acidic SMase but that increased ceramide
production occurred only in the presence of exogenous SM (Modrak, Cardillo et al.
2004). This study showed no difference in ceramide content in cells that were treated
with gemcitabine alone, while cells receiving SM alone had increased ceramide levels in
the absence of increased apoptosis. Cells receiving combination treatments had an
increase in the levels of ceramide present in the cells. In addition, mitochondrial
depolarization, apoptosis, and cell death increased when cells were treated with
gemcitabine and SM in combination versus individual agents.
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Our initial experiments demonstrated that exogenous SM could enhance
gemcitabine chemotherapy in a synergistic manner. Additional results in other pancreatic
cell lines and with other drugs demonstrated that this effect was not unique to our Panelgemcitabine model (Modrak, personal communication). Similar results were obtained in
a study by Tran, et al., where the use of sorafenib and nano liposomal ceramide inhibited
in vitro melanoma and breast cancer cell growth in a synergistic manner (Tran, Smith et
al. 2008). Flow cytometric analysis confirmed that the inclusion of SM with gemcitabine
treatment significantly increased the percentage of apoptotic cells compared to
gemcitabine used as a single agent. Together, this evidence supports the idea that the
levels of ceramide in gemcitabine treated Panel pancreatic cancer cells are not sufficient
to signal apoptosis induction and this is likely a result of insufficient SM substrate.
Pancreatic cancer cells have altered expression of bcl-2 family proteins (both
pro- and anti-apoptotic), which are crucial in determining chemosensitivity (Lawrence,
Davis et al. 2001). Studies to examine the role of Bc1-xl and Bax in determining
apoptosis induction in pancreatic cell lines (Colo357, PancTul and Panel) treated with
gemcitabine showed that Bc1-xl works to stabilize the mitochondrial transmembrane
potential while Bax destabilizes it (Schniewind, Christgen et al. 2004). Our studies,
showed treatment of Panel with gemcitabine as a single agent decreased both Bad and
Bel-xl expression and reduced Bcl-2 to undetectable levels. Flinz, et al., suppressed
Bc1-xl protein expression with the use of antisense oligonucleotide treatment in
pancreatic cancer lines, including Panel, and demonstrated an increase in apoptosis in
response to TRAIL (Hinz, Trauzold et al. 2000). Others have shown that Bcl-2 blocks
the release of factors essential for apoptosis preserving mitochondrial membrane potential

37

through the sequestering of Bax and Bad (Ng, Tsao et al. 2000; Scaffidi, Schmitz et al.
1999). In a study conducted by Bold, et al., over-expression of Bel-2 in pancreatic cancer
cell lines increased gemcitabine chemoresistance (Bold, Chandra et al. 1999). Since
untreated and SM treated Panel cells express Bcl-2, these cells would be more resistant
to chemotherapy. Conversely, the lack of Bcl-2 expression in the cells treated with
gemcitabine, both as a single agent and in combination with SM, indicates the cells
would be more chemosensitive.
The ratio of pro- to anti-apoptotic proteins is important in determining cell
survival and chemoresistance (Bold, Virudachalam et al. 2001; Mirjolet, Barberi-Heyob
et al. 2000). When anti-apoptotic proteins such as Bcl-2 and Bc1-xl are over-expressed,
Bax function is suppressed because of the formation of Bcl-2/Bax or Bcl-XL/Bax
heterodimers, thereby inhibiting apoptosis (Hinz, Trauzold et al. 2000; Lee, Hosotani et
al. 1999; Oltvai, Milliman et al. 1993). Increasing Bax levels after exposure to drugs
(Rampino, Yamamoto et al. 1997) or via transfection-mediated over-expression (Basu
and Haidar 1998) facilitates the formation of Bax/Bax homodimers and increases cell
death. Zhang, et al., found that, in the absence of an increase in Bax, a decrease in Bcl-2
alone resulted in altered Bax/Bcl-2 ratios and apoptosis (Zhang, Yu et al. 2000). In
addition, Adachi showed Bad to have the ability to induce apoptosis without interacting
with Bcl-2 (Adachi and Imai 2002). Our results agree with these studies in that we also
saw an increase in the pro- to anti-apoptotic protein ratio in the combination treatment
group as compared to the untreated cells. However, the lack of difference between the
combination and gemcitabine alone group suggests other factors are involved in the
initiation of cell death and that protein levels alone are not sufficient to guide the process.
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Mammalian cells will respond to cell injury by undergoing cell cycle arrest in an
attempt to repair the damage. If the damage is too severe, cells will usually signal for
apoptosis, but may undergo senescence (Hannun 1996; Schmitt, Fridman et al. 2002). In
the present study, we observed gemcitabine-induced apoptosis in Panel cells is enhanced
by the addition of SM. Cell cycle analysis of Panel cells demonstrated gemcitabine
decreased the G2/M cell population, resulting in an increase in the sub-Gi (apoptotic)
population. Although cell cycle arrest at the S phase is characteristic for gemcitabine
(Lawrence, Davis et al. 2001; Ng, Tsao et al. 2000), the inclusion of exogenous SM with
the gemcitabine treatment additionally increased the cells in the sub-Gj phase of the cell
cycle compared to single agent gemcitabine. Moreover, cells treated with SM alone
showed no significant changes in cell cycle distribution compared to the untreated, thus
reinforcing its non-toxic properties at the present concentration. Together, these results
support our previous observation that by increasing ceramide levels in the cell through
the administration of exogenous SM, there is an increase in the ability of cells to undergo
apoptosis.
The complex role of ceramide in the cell includes the regulation of signaling
pathways that result in G0/G 1 cell cycle arrest, which may be followed by apoptosis
(Bieberich 2004; Eto, Bennouna et al. 2003) or senescence (Ogretmen and Hannun
2004). Cells that have sustained DNA damage will be stopped at Gj and G2 checkpoints
of the cell cycle, where lethal damage will result in apoptosis; however, non-lethal
damage will result in autophagy or senescence (Kim, Emi et al. 2006). In our study,
morphological changes consistent with those observed in senescent cells, such as
increased cell size and flattened appearance, were evident in cells receiving gemcitabine
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treatment. In addition, we observed that, typically, approximately 35-45% of the cells
treated with gemcitabine alone remained metabolically viable. Together these
observations suggested that a percentage of pancreatic cancer cells escaped cell death and
instead entered into a state of senescence when treated with gemcitabine while the
inclusion of SM with gemcitabine treatment allowed the cells to enter into apoptosis.
Increased senescence-associated /5-galactosidase activity is the most commonly
used marker for identifying senescent cells. Studies have examined /5-galactosidase
expression in vivo in clinical cancers and have shown a percentage of cells became
senescent in tumors of treated patients and not in normal cells. One study with breast
tumor resections showed a greater percentage of senescence-associated /5-galactosidase
expression in women who underwent chemotherapy than in resections obtained from
untreated patients (about 10% in untreated patients and 42% in treated patients),
indicating an increase in senescence cells with treatment (te Poele, Okorokov et al. 2002).
Another study examined mice over-expressing the Bcl-2 gene treated with
cyclophosphamide. These results indicated an interruption in DNA replication in the
tumors as well as a significant increase in /5-galactosidase expression (Schmitt, Fridman
et al. 2002 ).
We explored the possibility of senescence induction in gemcitabine treated Panel
cells by examining the presence of senescence-associated /5-galactosidase activity. Our
findings showed a dose dependent increase in senescence-associated /5-galactosidase
activity in cells treated with gemcitabine alone, reaching a maximum at gemcitabine
concentrations above 10 nM and well below the IC50 (as determined by the MTT assay).
However, in the presence of SM, senescence-associated /5-galactosidase activity remained
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very low regardless of gemcitabine concentration. Together, this data demonstrated that
Panel cells treated with gemcitabine entered into senescence, however, by combining
gemcitabine and SM, the percentage of cells undergoing senescence was reduced.
Speculation exists as to the ability of senescent cell(s) to participate in tumor
growth, either by re-entering cell cycling or by providing growth factors that support
tumor growth (eg, VEGF). Both normal and treated cells undergo senescence under the
influence of the p53, p21, and p i 6 genes, all of which are often mutated or inactive in
pancreatic cancer cells (Roninson 2003). Mice that havep53, Rb, orp l6 mutations are
more likely to develop tumors, suggesting one role of senescence is to prevent the
formation of tumors (Ben-Porath and Weinberg 2004). Since the p i 6 gene is involved in
the inhibition of several cell cycle regulators, mutations of this gene have been
association with aggressive cell growth and up-regulation of tumor promoting factors
(Roninson 2003; Talar-Wojnarowska and Malecka-Panas 2006). Numerous studies have
provided evidence linking p i 6 mutations in pancreatic cancer to negative treatment
outcomes (Talar-Wojnarowska and Malecka-Panas 2006; Watanabe, Lee et al. 1997). An
in vivo study demonstrated that mice implanted with lymphomas and administered
several cycles of chemotherapy over time resulted in selection of mutant p i 6 and p53
genes, leading to tumors that not only re-grew, but were more aggressive in growth
(Kahlem, Dorken et al. 2004). In addition, the presence of non-functional pi 6 not only
prevents apoptosis but also causes cells to lose contact with the extracellular matrix,
which may increase the possibility of metastasis (Plath, Detjen et al. 2000).
The presence of /3-galactosidase in cells treated with gemcitabine in our findings,
made us examine other senescence-associated proteins. We observed an increase in Rb
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and p i 6 expression in Panel cells treated with SM treatment alone. However, compared
to the untreated cells, single agent gemcitabine treatment decreased expression of Rb and
reduced pi 6 , and p21 expression to an undetectable level. Although the levels of the
senescence related proteins we examined are not indicative of senescent cells, these
observations also fail to exhibit a pattern of protein expression to support apoptosis
induction in gemcitabine treated cells. In a study conducted by te Poele, et al., various
p53 wild-type cells lines treated with topoisomerase inhibitors exhibited characteristics of
senescence while in the presence of treatment and had constant levels of pi 6 which
increased only upon treatment removal (te Poele, Okorokov et al. 2002).
Cellular stress associated ceramide increases PP1 (protein phosphatase 1) and
PP2A activity which results in the dephosphorylation of the retinoblastoma protein (Rb)
and subsequent growth arrest (Hannun 1996; Perry and Hannun 1998; Pettus, Chalfant
et al. 2002; Ruvolo 2003). Senescence may be reversed if ceramide levels are decreased
in the cell (Venable, Lee et al. 1995). In a study conducted by Zhang, et al., Molt-4
T-leukemia cells were used to show the ability of ceramide to activate Rb, thus resulting
in cell cycle arrest (Zhang, Alter et al. 1996). Another study showed that short chain
ceramide will lead to dephosphorylation of Rb, which leads to cell death (Perry and
Hannun 1998). In another study using hepatocarcinoma cells, ceramide-mediated
Gi arrest occurred in a p53 independent manner through p21-mediated inhibition of cdk2
activity and dephosphorylation of Rb (Kim, Emi et al. 2006).
The results of our study provide evidence for the role of ceramide in both
apoptosis and senescence. Incubating Panel cells with water soluble Cs-ceramide led to
an induction of both apoptosis and senescence in a dose dependent manner with

42

senescence occurring at lower concentrations and apoptosis at higher concentrations. Our
results showed that /Tgalactosidase reached a maximum at 21.7 ± 1.5 pM, declining
thereafter. Cell death was not achieved at concentrations lower than 35 pM Cg-ceramide,
with the IC50 of 43.6 ± 2.5 pM. Together this data supports the idea that ceramide levels
are important in determining both apoptosis and senescence. Thus, by manipulating the
availability of ceramide, cells can be directed to undergo apoptosis.
Ceramide levels have been shown to quickly increase in the mitochondria
immediately before the activation of caspases that are associated with apoptosis induction
(Hannun 1996). However, ceramide levels have also been shown to remain elevated
throughout the process of apoptosis, which would indicate that ceramide is further
involved in the execution phase of apoptosis (Siskind 2005). Nevertheless, cells that
have become senescent will also have increased levels of intracellular ceramide (Venable,
Lee et al. 1995). Combining this data with the results of our studies, we propose
ceramide levels determine a cell’s ability to progress through the cell cycle, undergo
apoptosis, or enter into senescence (Figure 15). In normal cell proliferation, ceramide
levels increase during the Gi phase of the cell cycle and decrease after the Gj/S restriction
point. However, in response to cellular stress, the levels of ceramide increase and lead to
cell cycle arrest, where high concentrations of intracellular ceramide will induce
apoptosis. We postulate cellular senescence occurs with intermediary ceramide levels,
which maintain the cell in growth arrest but are insufficient for apoptosis.
Our proposed model for ceramide involvement in cell cycle control supports both
our hypothesis and the results obtained throughout the course of our study. Treating
cancer cells with gemcitabine activates aSMase to convert SM to ceramide (Modrak,
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Cardillo et al. 2004). Since tumor cells lack sufficient substrate for ceramide generation,
the addition of exogenous SM augments cellular SM signaling pools and allows increased
ceramide-mediated apoptosis signaling resulting from gemcitabine exposure. However,
if a sufficient amount of signaling ceramide fails to be generated, the cells cannot enter
apoptosis and will, instead, enter into a state of senescence.
Cancerous tumors are composed cells at different stages of division and with
mutations which impart chemoresistance. As studies continue to elucidate the complex
involvement of sphingolipids in cell signaling, it is becoming evident that ceramide plays
a critical role in a number of cell processes including the determination of cell survival.
Understanding the cellular origins and the key biochemical pathways that participate in
pancreatic cancer will offer new opportunities for the treatment of the disease. In so
doing, we may not only increase patient survival time but possibly find a cure for the
devastating illness that is pancreatic cancer.
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Figure 1. Sphingolipid metabolism. De novo synthesis of ceramide begins with the
condensation of serine and palmitoyl CoA to yield sphinganine, followed by acylation to
dihydroceramide and dehydrogenation to ceramide. Ceramide is then the root of all other
sphingolipids. The addition of glucose or galactose is the next step in the formation of
higher order gangliosides and is the major use of ceramide. The other major use of
ceramide is the production of SM via the transfer of a phosphocholine headgroup from
phosphatidylcholine by SM synthase. SM may be degraded to ceramide by the action of
SMases. Ceramide may be degraded to sphingosine by the action of ceramidase.
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Figure 2. Dose dependent response of Panel cells to gemcitabine in the presence of
SM. Panel cells were treated for 4 days with different concentrations of gemcitabine as a
single agent and in combination with 0.2 mg/ml (ICio) SM before assessment of viability
with MTT reagent. Typical results are shown. The IC50 values were determined to be
78.3 ± 13.7 nM for gemcitabine alone and 13.0 ± 3.0 nM for the combined treatment
(P < 0.001). These values represent the mean ± standard error from > 20 independent
experiments.
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Time (hrs)

Figure 3. Exogenous sphingomyelin uptake in Panel over time. Panel cells were
treated with [3H-methyl]choline-SM and solubilized at 0, 24, 48, 72, and 96 hours.
The data were normalized to total protein levels determined from cells treated with
non-radio active SM. The figure is representative of data obtained from > 3 experiments.
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2.2
33.0
52.8
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63.1

Figure 4. Flow cytometric analysis of Panel cells after gemcitabine ± SM treatment.
Panel cells were treated with 100 nM gemcitabine in the presence or absence of
0.2 mg/ml SM for 4 days. Apoptotic cells were detected by Annexin V-FITC and
propidium iodide staining. (A) Cells in the lower left quadrant are viable, in the upper
and lower right quadrants are apoptotic, and the left and right upper quadrants are dead.
(B) Values correspond with the percentage of healthy (viable, non-apoptotic), apoptotic,
and dead cells in the above experiment. The figure is representative of data obtained
from separate experiments with similar results.
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38.9 ± 6.8
48.4 ± 6.6
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8.6 ± 1.1
10.0 ± 1.2
53.5 ±3.9
59.3 ±4.4

Figure 5. Aggregated data for apoptotic Panel cells. Panel cells were treated with
100 nM gemcitabine in the presence or absence of 0.2 mg/ml SM and stained with
Annexin V-FITC and propidium iodide. Cells positive for Annexin V-FITC were
considered apoptotic and dead cells were positive for propidium iodide staining. (A) The
percentage of healthy (viable, non-apoptotic), apoptotic, and dead cells are represented as
the mean ± standard error of six separate experiments. (B) The table lists the values that
correspond with the graph above. P values < 0.05 are indicated by an asterisk (*).
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Figure 6. Expression levels of select bcl-2 family proteins in Panel cells. Western
blot analysis of Bad, Bax, Bcl-2, and B c1-xl expression from total cell lysates in Panel
cells following treatment with 100 nM gemcitabine and/or 0.2 mg/ml SM. The presence
of /3-actin was used for normalization of results. The figures are representative of three
independent experiments with similar results.
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Figure 7. Expression levels of select bcl-2 family proteins in treated Panel cells.
Levels of Bax, Bad, Bcl-2, and B c1-xl in Panel cells were determined by western blot
analysis. Bands were quantified using the TotalLab software, normalized to /3-actin,
and expressed as values relative to protein levels in the untreated cells. Changes in
expression in SM and gemcitabine treatments as individual agents were evaluated
against the untreated, and the combination treatment was compared to gemcitabine.
P values < 0.05 are noted with an asterisk (*). (A) The ratio of protein to /3-actin
expression is representative of the mean ± standard error from > 3 independent
experiments. (B) The table lists the values that correspond with the graph. ND = not
detected.
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Treatment
Untreated
Sphingomyelin
Gemcitabine
Combination

Bad
7.25 ± 1.30
6.74 ±2.61
7.38 ± 1.37
8.72 ± 0.44

Bax
2.54 ± 1.76
-2.30 ± 0.21*
2.15 ±0.94
0.15 ±0.21*

Bcl-2
3.28 ± 1.37
3.24 ±0.11
3.44 ±0.31
2.76 ±0.40*

Bcl-xL
3.33 ± 1.56
-0.39 ± 1.87*
3.11 ±0.72
2.83 ± 0.78

Figure 8. Analysis of selected bcl-2 family gene expression in Panel cells. RNA
extracted from Panel cells treated with 100 nM gemcitabine in the absence and
presence of 0.2 mg/ml SM was examined by RT-PCR arrays. (A) The graph shows the
fold change in Bad, Bax, Bcl-2, and Bcl-xi gene expression normalized to untreated
Panel cells in three separate experiments. Values greater than 2 require further
investigation. (B) The table summarizes the average ACt values from separate
experiments. P values < 0.05 are indicated by an asterisk (*).
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Figure 9. Analysis of apoptosis related gene expression in Panel cells. Panel cells
were treated with 100 nM gemcitabine and/or 0.2 mg/ml SM for 4 days. RNA was
isolated and apoptosis related genes were analyzed with RT-PCR arrays. The figure
summarizes the fold change in gene expression normalized to untreated Panel cells in
three separate experiments.
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Figure 10. Cell cycle distribution of Panel cells. Panel cells were treated with
100 nM gemcitabine alone and in combination with 0.2 mg/ml SM for 4 days. Cells
were fixed, stained with propidium iodide, and analyzed by flow cytometry. (A) The
figure is representative of data obtained from > 3 independent experiments with similar
results. (B) The table expresses values characteristic of Panel cell cycle as observed in
separate experiments. P values < 0.05 are indicated by an asterisk (*).
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Figure 11. Comparison of /3-gaIactosidase activity in Panel cells treated with
gemcitabine in the presence and absence of SM. Panel cells were incubated in the
presence of C 12-FDG, gemcitabine and/or SM for 4 days. Cells were analyzed by flow
cytometry and mean channel fluorescence was determined. Treated cells were
normalized to the untreated. The figure is representative of three independent
experiments with similar results.
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Figure 12. Western blot analysis of proteins associated with senescence in Panel
cells. Expression of Rb, pi 6, and p21 in Panel cells in total cell lysates was determined
by western blot analysis. /3-actin was used as an internal control. The figures are
representative of triplicate experiments with similar results.
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Figure 13. Quantification of senescence related proteins in treated Panel cells.
Total cellular levels of Rb, p i6, and p21in Panel cells treated with 100 nM gemcitabine
and/or 0.2 mg/ml SM were determined by western blot analysis. Bands were quantified
by the TotalLab software and were normalized to /3-actin. P values < 0.05 are noted with
an asterisk (*). (A) The ratio of protein to (3-actin expression was determined and
normalized to the untreated from three independent experiments. (B) The table lists the
values that correspond with the graph. ND = not detected.
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% Non-viable
Figure 14. Flow cytometric analysis of viability and /5-galactosidase activity in
Panel cells following Cs-ceramide treatment. Cells were treated with Cg-ceramide for
4 days in the presence of C 12-FDG for the identification of senescent cells. Viability was
determined by propidium iodide staining (□) and senescence by /3-galactosidase
activity (o). The figure is representative of three independent experiments with similar
results.
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Figure 15. Proposed model for the involvement of ceramide in cell cycle control.
The level of ceramide in the cell is proposed to determine whether a cell progresses
through the cell cycle, enters senescence, or initiates apoptosis. During the cell cycle,
ceramide levels increase until the restriction point in Gj. Cell cycle progression occurs
when ceramide levels are low, senescence when levels are moderate, and apoptosis when
levels are high.

67

